Carcinoid Tumor: Clinical Trials

11 trials for Carcinoid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 active not recruiting, 2 terminated, 1 recruiting. 11 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Completed 4, Active not recruiting 2, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1
Phase 21Completed 1

Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Phase 3RecruitingWashington University School of Medicine2402026-11-022026-11-06
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid
Phase 3Active not recruitingCrinetics Pharmaceuticals Inc.1412025-11-192026-10-15
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RYZ101, Everolimus, Sunitinib - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Phase 3Active not recruitingRayzeBio, Inc.3432022-03-242026-10-05
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Telotristat Ethyl, Lanreotide - Small Intestinal NET, Carcinoid Heart Disease
Phase 3WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2020-04-012020-02-05
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Lanreotide, Placebo - Carcinoid Syndrome
Phase 3CompletedIpsen1152009-05-012022-10-14
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Pasireotide, Octreotide - Symptomatic Refractory Resistant Carcinoid Disease
Phase 3CompletedNovartis Pharmaceuticals1862008-04-012013-07-30
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Octreotide, Placebo, Everolimus - Carcinoid Tumor, Malignant Carcinoid Syndrome
Phase 3CompletedNovartis Pharmaceuticals4292006-12-012014-11-21
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Indium-111 pentetreotide - Neuroendocrine Tumors
Phase 2 / Phase 3CompletedRadio Isotope Therapy of America2002005-08-012023-04-03
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
5-Hydroxy-Tryptamine - Carcinoid Tumors, Neuroendocrine Tumors
Phase 3TerminatedUniversity of Western Ontario, Canada82005-05-012018-04-13
Comparison of Lanreotide AutogelĀ® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) - Malignant Carcinoid Syndrome
Phase 3TerminatedIpsen42004-07-012020-04-30
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
123I-meta-iodobenzylguanidine - Pheochromocytoma, Neuroblastoma
Phase 3UnknownVancouver Coastal Health2011-06-15

Narrower conditions

Neuroendocrine Tumors (6)  ·  Serotonin Syndrome (4)  ·  Malignant Carcinoid Syndrome (2)  ·  Paraganglioma (2)  ·  Pheochromocytoma (2)  ·  Adenoma, Islet Cell (1)  ·  Carcinoid Heart Disease (1)  ·  Carcinoid Tumors, Intestinal (1)  ·  Carcinoma (1)  ·  Carcinoma, Medullary (1)  ·  Diarrhea (1)  ·  Flushing (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)  ·  Neoplasms (1)

Broader conditions

Adenocarcinoma (11)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms, Germ Cell and Embryonal (11)  ·  Neoplasms, Glandular and Epithelial (11)  ·  Neoplasms, Nerve Tissue (11)  ·  Neuroectodermal Tumors (11)  ·  Carcinoma (10)  ·  Neoplasms (10)  ·  Neuroendocrine Tumors (5)  ·  Chemically-Induced Disorders (4)  ·  Drug-Related Side Effects and Adverse Reactions (4)  ·  Carcinoma, Neuroendocrine (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)

Interventions

Octreotide (3)  ·  lanreotide (3)  ·  Everolimus (2)  ·  Receptor-Like Protein Tyrosine Phosphatases, Class 2 (1)  ·  Serotonin (1)  ·  Sunitinib (1)  ·  pasireotide (1)  ·  telotristat ethyl (1)

Sponsors

Ipsen (2)  ·  Novartis Pharmaceuticals (2)  ·  Crinetics Pharmaceuticals Inc. (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Radio Isotope Therapy of America (1)  ·  RayzeBio, Inc. (1)  ·  University of Western Ontario, Canada (1)  ·  Vancouver Coastal Health (1)  ·  Washington University School of Medicine (1)

Countries

United States (8)  ·  Canada (5)  ·  Belgium (4)  ·  Brazil (4)  ·  France (4)  ·  Spain (4)  ·  Germany (3)  ·  Italy (3)  ·  Poland (3)  ·  United Kingdom (3)  ·  Argentina (2)  ·  Czechia (2)  ·  Netherlands (2)  ·  Sweden (2)  ·  Australia (1)

Top investigators

Angela Lamarca (1)  ·  Daniel Worsley, MD (1)  ·  Ebrahim Delpassand, M.D. (1)  ·  Juan Valle (1)  ·  Nikolaos Trikalinos, MD, MS (1)  ·  Stan HM Van Uum, MD, PhD (1)  ·  Ye Yuan, MD (1)

Results publications

PMID 22119496, PMID 23187897, PMID 27214300, PMID 28444114, PMID 31754316, PMID 38753757

NIH funding

2004 (1)